Home › Funds › Catalio Capital Management, LP › SNDX

Catalio Capital Management, LP position in SNDX

SYNDAX PHARMACEUTICALS INC · Health Care

Catalio Capital Management, LP reported holding 1,215,698 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$26.6M, representing 4.99% of its reported portfolio and ranking #5 among its reported holdings. Catalio Capital Management, LP has disclosed SNDX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)1.22M sh
Reported value held$26.58M
Portfolio Weight4.99%
First reportedQ1 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Catalio Capital Management, LP's SNDX position evolved

Catalio Capital Management, LP first disclosed a stake in SNDX in Q1 2025 at 1,733,701 shares (US$21.3M). The position peaked in Q2 2026 at 1,215,698 shares, worth US$26.6M. Across 6 filings, Catalio Capital Management, LP increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,215,698 shares valued at US$26.6M — an increase of 172,028 shares quarter over quarter.. Notable position changes include a 26% trim in Q4 2025 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 1.73M $21.30M New
Q2 2025 2.10M $19.71M Add
Q3 2025 1.61M $24.84M Reduce
Q4 2025 1.20M $25.14M Reduce
Q1 2026 1.04M $24.38M Reduce
Q2 2026 1.22M $26.58M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SNDX and 13F data

SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SNDX

All SNDX fund holders →

FAQ

How long has Catalio Capital Management, LP held SNDX?

Catalio Capital Management, LP has disclosed SNDX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is Catalio Capital Management, LP's current position in SNDX?

As of Q2 2026, Catalio Capital Management, LP holds 1.22M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $26.58M, representing 4.99% of its reported portfolio and ranking #5.

Has Catalio Capital Management, LP been buying or selling SNDX?

In the latest 13F filing (Q2 2026), Catalio Capital Management, LP increased its position in SNDX. The position peaked in Q2 2026 at 1.22M shares.

Which other funds hold SNDX?

Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.